Fusion glycoprotein產(chǎn)品信息
英文名稱：Respiratory syncytial virus F protein
中文名稱：呼吸道合胞病毒F蛋白
靶點別稱：Fusion glycoprotein,F protein,Nipah virus,Hendra virus
物種：Nipah virus
屬性：Protein
標記：Unconjugated
內毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Fusion glycoprotein分子背景
Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.
關鍵字： Fusion glycoprotein;F protein;Fusion glycoprotei蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。